tbuckley/cabot-search huggingface dataset:
Highlights of Recent Findings on Quality-of-Life Management for Patients With Cancer and Their Survivors
Authors: Charles L. Shapiro
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The relationship between epidermal growth factor receptor (EGFR) mRNA levels and protein expression in primary colorectal cancer and corresponding liver metastases
Authors: H. Kuramochi, K. Hayashi, G. Nakajima, K. D. Danenberg, P. V. Danenberg, M. Yamamoto
Journal: Journal of Clinical Oncology (2008)

15021 Background: As it has been well known that epidermal growth factor receptor (EGFR) is strongly related to tumor proliferation and metastasis, several EGFR-targeted drugs have been developed recently. It has been reported that EGFR mRNA levels are associated with response probability in patients treated with EGFR-targeted drugs. We had reported that EGFR mRNA levels in primary colorectal cancer (CRC) are correlated with those in corresponding liver metastases. In this study, our aim was to determine how EGFR mRNA levels are associated with protein expression levels evaluated by immunohistochemistry, and whether immunohistochemical expression in primary CRC correlate with those in liver metastases, as well as mRNA expression. Methods: Thirty-two pairs of primary CRC and corresponding liver metastases were analyzed. Formalin-fixed, paraffin-embedded tumor specimens were dissected using laser-captured microdissection and EGFR mRNA expression levels were quantified by real-time RT-PCR. Same samples were also evaluated EGFR immunohistochemistry. Results: There was a significant correlation for EGFR mRNA expression between primary cancer and corresponding liver metastases (rs=0.78, p<0.0001). In protein levels, 21 of 25 patients with negative expression in primary cancer showed negative in liver metastases, and 4 out of 7 with positive in primary cancer also showed positive in liver metastases (p=0.046, Fisher’s Exact Test). When protein expression and mRNA levels were compared in liver metastases, the patients with positive protein expression showed significantly higher mRNA levels than those with negative protein expression. However no differences in mRNA levels were observed between positive and negative protein expressions in primary CRC. Conclusions: EGFR protein expression showed similar results with mRNA levels in liver metastases, though discrepancy was observed in primary CRC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Response Genetics Inc.
Recurrent STAT6 Mutations In Follicular Lymphoma
Authors: Sami Malek, Mark S. Kaminski, Hongxiu Li, Peter Ouillette, Sian Jones, Heather Fox, Kathryn Jacobi, Kamlai Saiya-Cork, Dale Bixby, Daniel Lebovic, Kerby Shedden, Michael Sabel, Lawrence Marentette, Vincent Cimmino, Alfred Chang, Mehmet Yildiz
Journal: Blood (2013)
Racial Differences In Thrombin-Induced Human Platelet PAR4 Reactivity
Authors: Leonard C. Edelstein, Lukas M Simon, Raul Teruel Montoya, Michael Holinstat, Edward Chen, Angela Bergeron Woodley, Xiango Kong, Srikanth Nagalla, Narla Mohandas, David Cohen, Jing-fei Dong, Chad A Shaw, Paul F Bray
Journal: Blood (2013)
Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.
Authors: S.J. Kim, W.S. Kim
Journal: Annals of Oncology (2016)
Abstract 3625: Expression of CRBN binding protein AGO2 plays important roles for myeloma cell growth
Authors: Qinqin Xu, Yuexian Hou, Paul Langlais, Patrick Erickson, James Zhu, Changxin Shi, Moulun Luo, Yuanxiao Zhu, Lawrence Mandarino, Keith Stewart, Xiu-Bao Chang
Journal: Cancer Research (2015)

Abstract Immunomodulatory drugs (IMiDs) are therapeutically active compounds that bind to the E3 ubiquitin ligase substrate recruiter cereblon (CRBN) and induce many cellular responses, including cytotoxicity. We had found that the expression of CRBN in multiple myeloma (MM) cells provided the basis for their responses to IMiDs. In this report, we have identified argonaute 2 (AGO2) as a new member of CRBN-downstream binding protein and found that: 1) the steady-state levels of CRBN in IMiD-sensitive cells are significantly higher than in IMiD-resistant cells; 2) the steady-state levels of AGO2 in IMiD-sensitive cells are significantly less compared to IMiD-resistant cells, suggesting that CRBN plays a role in regulating AGO2. AGO2 is a component of microRNA (miRNA)-induced silencing complexes and plays an important role in miRNA maturation and function. The matured miRNAs are considered as key regulators of almost all cellular pathways. Treatment of IMiD-sensitive MM cells with lenalidomide, an IMiD, significantly increased CRBN, decreased both AGO2 and miRNAs and inhibited cell growth. In contrast, although treatment of IMiD-resistant MM cells with lenalidomide moderately increased CRBN and decreased both AGO2 and miRNAs, this treatment did not significantly inhibit cell growth. However, silencing of AGO2 with small hairpin RNA significantly decreased both AGO2 and miRNAs and inhibited cell growth regardless of whether the cells are sensitive or resistant to IMiDs. Therefore, AGO2 could be considered as a new drug target for overcoming IMiDs resistance in MM cells. Citation Format: Qinqin Xu, Yuexian Hou, Paul Langlais, Patrick Erickson, James Zhu, Changxin Shi, Moulun Luo, Yuanxiao Zhu, Lawrence Mandarino, Keith Stewart, Xiu-Bao Chang. Expression of CRBN binding protein AGO2 plays important roles for myeloma cell growth. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3625. doi:10.1158/1538-7445.AM2015-3625
Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes
Authors: Amy Trentham-Dietz, Karla Kerlikowske, Natasha K. Stout, Diana L. Miglioretti, Clyde B. Schechter, Mehmet Ali Ergun, Jeroen J. van den Broek, Oguzhan Alagoz, Brian L. Sprague, Nicolien T. van Ravesteyn, Aimee M. Near, Ronald E. Gangnon, John M. Hampton, Young Chandler, Harry J. de Koning, Jeanne S. Mandelblatt, Anna N.A. Tosteson
Journal: Annals of Internal Medicine (2016)

Background: Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design: Collaborative simulation modeling using national incidence, breast density, and screening performance data. Setting: United States. Patients: Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention: Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-positive results to breast cancer deaths averted. Results: Screening benefits and overdiagnosis increase with breast density and RR. False-positive mammograms and benign results on biopsy decrease with increasing risk. Among women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, breast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted increased with annual versus biennial screening for women aged 50 to 74 years at all levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heterogeneously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold higher. Triennial screening for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $100 000 per QALY gained. Limitation: Models did not consider women younger than 50 years, those with an RR less than 1, or other imaging methods. Conclusion: Average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density receiving annual screening will maintain a similar or better balance of benefits and harms than average-risk women receiving biennial screening. Primary Funding Source: National Cancer Institute.
Maybe It’s Not the Gluten
Authors: Daphne Miller
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PWE-017 Colonic polyp size estimation and distribution in a screening naive population: Abstract PWE-017 Table 1
Authors: J Schembri, K Caruana, J Delicata, P Ellul
Journal: Gut (2015)

<h3>Introduction</h3> Polyp distribution can effect the efficacy and modality of a population screening method. A number of studies in the past demonstrated that a significant proportion of adenomas lie proximal to the splenic flexure,<sup>1</sup>however sigmoidoscopy is being increasingly used for screening purposes. We set out to identify distribution and characteristics of colonic polyps in a screening naive population. <h3>Method</h3> We conducted a retrospective analysis of 1462 diagnostic and surveillance colonoscopies performed at MDH Malta, between 2012 and 2014. 587 reports contained the term polyp and were further analysed looking at demographics and polyp characteristics. <h3>Results</h3> Overall mean age was 60.5 years and 58.7% (n = 341) were males. A total of 1141 polyps were identified with an average of 0.8 polyps per procedure. Overall adenoma detection rate (ADR) was 27.5%. ADR was significantly higher in males (34.4%) than in females (21.4%); Chi-square p = 0.00. 88.2% (n = 1042) of polyps were diminutive (1–5 mm), 3.8% (n = 45) were small (6–9 mm) and the remaining 8.0% (n = 7795) were large (&gt;=10 mm). Table 1demonstrates that whereas adenomas were prevalent throughout the entire colon, hyperplastic polyps were more prevalent distally (p = 0.00). Polyps with advanced histological features were however mostly left sided (p = 0.00); 79.2% and 80.0% of polyps with high grade dysplasia and submucosal invasion respectively. This was also true for large polyps, 78.9% of which (n = 59/95) were distal to the splenic flexure. Polyp size estimation at endoscopy was found to be an overestimate of the pathological specimen measurement (respective means = 8.41 mm and 6.17 mm; paired t-test p = 0.00), and this would have reduced polyp size classification across the 10 mm threshold in 33 instances. <h3>Conclusion</h3> Since a large proportion of advanced polyps were situated distal to the splenic flexure, sigmoidoscopy seems to be a plausible alternative to full colonoscopy as a screening alternative. Polyp size estimation at endoscopy resulted in mis-sizing of 33.3% of polyps across the 10 mm threshold and surveillance advice should be based on pathology specimens, when possible. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Lemmel GT, Haseman JH, Rex DK, Rahmani E. Neoplasia distal to the splenic flexure in patients with proximal colon cancer. <i>Gastrointest Endosc</i>. 1996 Aug;44(2):109-11
Abstract 16949: Failing Fontan: Genesis of a Subpulmonary Neo-ventricle From Engineered Heart Tissue
Authors: Daniel Biermann, Alexandra Eder, Hatim Seoudy, Florian Arndt, Tillmann Schuler, Kersten Peldschus, Michael G. Kaul, Hermann Reichenspurner, Thomas Mir, Arlindo Riso, Rainer Kozlik-Feldmann, Arne Hansen, Thomas Eschenhagen, Joerg S. Sachweh
Journal: Circulation (2015)

Introduction: Fontan palliation is the treatment of choice for patients with morphological or functional univentricular hearts. The unphysiologic and non-pulsatile pulmonary blood flow results in multiorgan complications and a poor long-term outcome. We evaluated graft survival and histomorphology of a pulsatile Fontan conduit generated from Engineered Heart Tissue (EHT) after implantation in a rat model. Hypothesis: We hypothesized that EHT matures and remains contractile in the setting of venous (Fontan-like) preload. Methods: EHT was generated from ventricular cardiomyocytes of neonatal Wistar rats, fibrinogen, thrombin and DMEM. After culture for 14 days constructs were implanted around the right superior vena cava of Wistar rats (n=12, 300-350 g). Immunosupression was achieved by daily subcutaneous injection of Cyclosporin A (25 mg/kg BW) and Methylprednisolone (2 mg/kg BW). MRI (Bruker) was used to assess condensation of EHTs in vivo. Animals were euthanized after 7, 14, 28 and 56 days postoperatively for histomorphological analysis. Transmission electron microscopy was used to evaluate sarcomeric integrity of cardiomyocytes within the construct. Results: In culture, EHTs started beating around day 8 and remained contractile in vivo throughout the experiment (d7=3/3, d14=2/3, d28=3/3, d56=2/3). All animals survived circumferential implantation of EHTs around the right SVC via a right thoracotomy. MRI (d14, n=3) revealed no constriction or stenosis of the SVC by the constructs. Hematoxylin and Eosin staining showed densely packed bundles of cardiomyocytes within the EHT conduit and intense vascularisation. Immunolabeling of actinin and connexin 43 indicated adequate maturation of cardiomyocytes after grafting around the right SVC in rats. Conclusions: EHTs placed around the superior caval vein of Wistar rats survive and contract for a considerable time after implantation. Histomorphology revealed a matured phenotype of grafted cardiomyocytes and an adequate vascularisation. The functional benefit of a contractile neo-ventricle to propel pulmonary blood flow in Fontan patients remains to be evaluated.
Observations With Simultaneous 18F-FDG PET and MR Imaging in Peripheral Artery Disease
Authors: Isabel Dregely, Tobias Koppara, Stephan G. Nekolla, Jörg Nährig, Kristin Kuhs, Nicolas Langwieser, Marijana Dzijan-Horn, Carl Ganter, Michael Joner, Karl-Ludwig Laugwitz, Markus Schwaiger, Tareq Ibrahim
Journal: JACC. Cardiovascular imaging (2016)
Micro–Computed Tomography Comparison of Preterminal Bronchioles in Centrilobular and Panlobular Emphysema
Authors: Naoya Tanabe, Dragoş M. Vasilescu, John E. McDonough, Daisuke Kinose, Masaru Suzuki, Joel D. Cooper, Peter D. Paré, James C. Hogg
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Very little is known about airways that are too small to be visible on thoracic multidetector computed tomography but larger than the terminal bronchioles.To examine the structure of preterminal bronchioles located one generation proximal to terminal bronchioles in centrilobular and panlobular emphysema.Preterminal bronchioles were identified by backtracking from the terminal bronchioles, and their centerlines were established along the entire length of their lumens. Multiple cross-sectional images perpendicular to the centerline were reconstructed to evaluate the bronchiolar wall and lumen, and the alveolar attachments to the outer airway walls in relation to emphysematous destruction in 28 lung samples from six patients with centrilobular emphysema, 20 lung samples from seven patients with panlobular emphysema associated with alpha-1 antitrypsin deficiency, and 47 samples from seven control (donor) lungs.The preterminal bronchiolar length, wall volume, total volume (wall + lumen), lumen circularity, and number of alveolar attachments were reduced in both centrilobular and panlobular emphysema compared with control lungs. In contrast, thickening of the wall and narrowing of the lumen were more severe and heterogeneous in centrilobular than in panlobular emphysema. The bronchiolar lumen was narrower in the middle than at both ends, and the decreased number of alveolar attachments was associated with increased wall thickness in centrilobular emphysema.These results provide new information about small airways pathology in centrilobular and panlobular emphysema and show that these changes affect airways that are not visible with thoracic multidetector computed tomography scans but located proximal to the terminal bronchioles in chronic obstructive pulmonary disease.
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
Authors: K. Reich, A. Blauvelt, A. Armstrong, R.G. Langley, T. Fox, J. Huang, C. Papavassilis, E. Liang, P. Lloyd, G. Bruin
Journal: British Journal of Dermatology (2016)

The proinflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis. Secukinumab, a fully human monoclonal antibody (mAb) that selectively targets IL-17A, has been demonstrated to be highly efficacious for the treatment of moderate-to-severe psoriasis, starting at early time points, with a sustained effect and a favourable safety profile. mAb therapies may be associated with production of antidrug antibodies (ADAs) that can affect drug pharmacokinetics, diminish response or cause hypersensitivity reactions.To investigate the immunogenicity of secukinumab across six phase III clinical trials in which patients with plaque psoriasis were treated with secukinumab for up to 52 weeks and additionally followed up at week 60.Immunogenicity in patients with plaque psoriasis exposed to secukinumab was evaluated at baseline and at weeks 12, 24, 52 and 60. Treatment-emergent (TE)-ADAs were defined as a positive ADA signal detected in post-treatment samples from patients with a negative baseline signal. Confirmed positive samples were further analysed for their drug-neutralizing potential.Among 2842 patients receiving secukinumab and evaluated for ADAs, 11 (0·4%) developed TE-ADAs. Associations between TE-ADAs and secukinumab dose, frequency or mode of administration were not observed. Neutralizing antibodies were detected in three of nine evaluable patients with TE-ADAs.Secukinumab immunogenicity was low, as shown by TE-ADA detection in only 11 of 2842 (0·4%) patients with moderate-to-severe plaque psoriasis treated with secukinumab. All but one of the patients with TE-ADAs were biologic naive. Neither TE-ADAs nor neutralizing antibodies were associated with loss of secukinumab efficacy or issues of clinical concern.
Defective proviruses rapidly accumulate during acute HIV-1 infection
Authors: Katherine M Bruner, Alexandra J Murray, Ross A Pollack, Mary G Soliman, Sarah B Laskey, Adam A Capoferri, Jun Lai, Matthew C Strain, Steven M Lada, Rebecca Hoh, Ya-Chi Ho, Douglas D Richman, Steven G Deeks, Janet D Siliciano, Robert F Siliciano
Journal: Nature Medicine (2016)